{
  "docId": "019de073-7953-75ff-b7a7-421adee0c76c",
  "docSlug": "f2ba5faea717d1fc1a89b119873b0327",
  "documentTitle": "Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides",
  "authorId": "anebulo-pharmaceuticals",
  "authorName": "Anebulo Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 53,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7953-75ff-b7a7-421adee0c76c/47",
  "deckHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c",
  "deckJsonHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c.json",
  "deckAnchorHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.8,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "list",
      "text": "Next Steps: Initial evaluation in nonclinical PK models; Selection of a lead formulation for clinical development; GMP scale up and initiation of IND enabling studies; Scope of required studies depends on PK comparability versus existing safety data; First in human dosing of parenteral formulation would be a Phase 1 study; New opportunities for additional IP coverage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ee3f4f6-1107-4619-9f97-dddda953a69f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.8,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Status: Potential for use in ACI subjects unable to swallow oral capsules; Preferred route of administration for pediatric subjects; Targeting single dose IV or IM injection to be administered in Emergency Department; Multiple novel prototype parenteral formulations currently being evaluated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "944362f6-2058-4353-9e9b-f8a4fff78253",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ANEB-001 Parenteral Product Development Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "005df51b-58ae-41ea-bf9a-e04ee34603f6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 48,
      "from": 13,
      "beatId": "684e64de-8d19-434b-83aa-4bfe1e4eb804",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 13-48 present ANEB-001 as a solution, detailing its pharmacology, clinical trial results, and development plan.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}